Metraipolis › archive › dc_6776095bc63d

Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular risk — Europe PMC PMID:42180015

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42180015
DOI
10.1093/crocol/otag039
License (as archived)
solo-consultazione
Archived
2026-11-03T13:42:32.925Z
SHA-256 of the archived text
0f1902c30d5692fa9232121a400e76c9ab711422479c8bfbfc74c96c70961bc9
Stable URL of this page
https://metraipolis.com/documento/dc_6776095bc63d

How to cite

Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular risk — Europe PMC PMID:42180015 — Europe PMC (en), https://europepmc.org/article/MED/42180015 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6776095bc63d (Metraipolis archive dc_6776095bc63d, sha256 0f1902c30d5692fa9232121a400e76c9ab711422479c8bfbfc74c96c70961bc9)
BibTeX
@misc{dc6776095bc63d,
  title = {Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular risk — Europe PMC PMID:42180015},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42180015},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6776095bc63d; sha256 0f1902c30d5692fa9232121a400e76c9ab711422479c8bfbfc74c96c70961bc9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180015. Agents can read the archived copy with the MCP tool read_document.